One dose of Pfizer and Moderna vaccines is 80% effective, CDC says

A single dose of COVID-19 vaccine from Pfizer and Moderna, which require two inoculations, it is 80% effective in preventing contagion, according to a study published on Monday by the Centers for Disaster Control and Prevention (CDC) of the United States.

This effect was observed two weeks after the first dose of the study, conducted with 4.000 health workers between December 14 and March 13. “This studio shows that our national vaccination efforts are working ”, announced the director of the CDC, Rochelle Wallensky, at a press conference.

The results showed that the risk of infection was reduced by 90% in people who received the two recommended doses; which began to have a protective effect even after the first injection, by reducing the risk of contagion by 80% two weeks later.

“Authorized mRNA vaccines against COVID-19 provided substantial and early protection in the real world against infection for our country’s health workers, first responders and other essential frontline workers, ”the expert added.

This results Adds to a growing body of evidence that vaccines not only stop symptomatic illnesses, but also the infection itself, which makes it an important tool in slowing the spread of the virus.

The research coincides with the acceleration of the vaccination process in the United States, with more than 3 million doses administered daily. Since yesterday, Sunday, 93 million people had received at least one dose of some of the vaccines licensed in the North American country, and some 51 million people were already fully vaccinated.

The American President, Joe Biden, The Independence Day in the country, July 4, marked the date of a return to relative normality. United States granted emergency use authorization for Pfizer and Moderna vaccines, and to Johnson & Johnson, which is a single dose and whose efficacy is a little lower. The country, the most affected in the world by the pandemic, records more than 30.2 million infections with COVID-19 and more than 549,000 deaths, according to the independent count of the Johns Hopkins University.

“SARS-CoV-2 will not go away and we will live with this virus, we believe, forever. The new coronavirus, which has crippled global economies and collapsed hospitals, will be with us forever “declared earlier this year Stéphane Bancel, executive director of the American laboratory Modern who developed an effective vaccine against COVID-19.

In relation to the appearance of new recent mutations of the coronavirus which has experts around the world on alert, the specialist added: “Health officials will need to constantly monitor new variants of the virus, so that scientists can produce vaccines to fight them“. These new variants of the virus can lead to more complex behavior of the pathogen, for example by increasing its contagion, by being more lethal or by becoming more resistant to vaccines or to treatments against the disease.

Data from unpaired research published on February 18 in Medrxiv suggested that the two COVID-19 vaccines not only prevent symptoms of the SARS-CoV-2 virus, but also possible new infections.

A team from the prestigious institution Mayo Clinic examined more than 31,000 people in four states of the United States who had received at least one of the two doses that make up the immunization schedules in that country. This is how found that inoculants were over 80% effective in preventing infection 36 days after the first dose, on average. At 15 days, the efficacy was detected at 75%, and seemed to show 89% from 36 days after the second dose, as reported by the scientific publication.

For the doctor Christopher Murray, director of the Institute for Health Metrics and Evaluation at the University of Washington, “America is unlikely to achieve herd immunity to the virus until winter. We know COVID-19 is really seasonal, so when next winter arrives, we have to have a much higher level of protection to stop it in its path ”, he said in dialogue with the CNN.

With information from EFE

KEEP READING: